These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 23836561)
1. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Ravandi F; Jorgensen JL; Thomas DA; O'Brien S; Garris R; Faderl S; Huang X; Wen S; Burger JA; Ferrajoli A; Kebriaei P; Champlin RE; Estrov Z; Challagundla P; Wang SA; Luthra R; Cortes JE; Kantarjian HM Blood; 2013 Aug; 122(7):1214-21. PubMed ID: 23836561 [TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885 [TBL] [Abstract][Full Text] [Related]
3. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014 [TBL] [Abstract][Full Text] [Related]
4. Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study. Salah-Eldin M; Abousamra NK; Azzam H Med Oncol; 2014 May; 31(5):938. PubMed ID: 24692146 [TBL] [Abstract][Full Text] [Related]
5. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Short NJ; Jabbour E; Sasaki K; Patel K; O'Brien SM; Cortes JE; Garris R; Issa GC; Garcia-Manero G; Luthra R; Thomas D; Kantarjian H; Ravandi F Blood; 2016 Jul; 128(4):504-7. PubMed ID: 27235138 [TBL] [Abstract][Full Text] [Related]
6. Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. Appelmann I; Rillahan CD; de Stanchina E; Carbonetti G; Chen C; Lowe SW; Sherr CJ Blood; 2015 Feb; 125(9):1444-51. PubMed ID: 25499760 [TBL] [Abstract][Full Text] [Related]
7. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599 [TBL] [Abstract][Full Text] [Related]
8. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Benjamini O; Dumlao TL; Kantarjian H; O'Brien S; Garcia-Manero G; Faderl S; Jorgensen J; Luthra R; Garris R; Thomas D; Kebriaei P; Champlin R; Jabbour E; Burger J; Cortes J; Ravandi F Am J Hematol; 2014 Mar; 89(3):282-7. PubMed ID: 24779033 [TBL] [Abstract][Full Text] [Related]
9. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. de Labarthe A; Rousselot P; Huguet-Rigal F; Delabesse E; Witz F; Maury S; Réa D; Cayuela JM; Vekemans MC; Reman O; Buzyn A; Pigneux A; Escoffre M; Chalandon Y; MacIntyre E; Lhéritier V; Vernant JP; Thomas X; Ifrah N; Dombret H; Blood; 2007 Feb; 109(4):1408-13. PubMed ID: 17062730 [TBL] [Abstract][Full Text] [Related]
10. Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy. Ohno R; Curr Hematol Malig Rep; 2006 Sep; 1(3):180-7. PubMed ID: 20425349 [TBL] [Abstract][Full Text] [Related]
11. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595 [TBL] [Abstract][Full Text] [Related]